With the rapid development of TPD, which induces the proximity of E3 ubiquitin ligase to the target protein, resulting in ubiquitination and degradation of the target protein in a proteasome‐dependent manner, TPD‐mediated GSPT1 degradation therapy has been an attractive strategy for targeting GSPT1 in tumors.[22, 23] As one strategy of TPD, Molecular glue degraders (MGDs) that target GSPT1 degradation, such as CC‐885 and CC‐90009 against acute myeloid leukemia (AML)[24, 25] and MRT‐2359 against MYC‐driven cancers[26] have shown promising antitumor activities in preclinical models. Here, PRKN is linked to cancer.